Documents

A list of downloadable documents created during development.

Background information

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - guidance review - May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appraisal consultation

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the provisional matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentator comments on the draft remit and draft scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix - July 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment - scoping - June 2012

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft matrix

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee and commentators comments on the draft scope

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): equality impact assessment

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix B - draft scope for consultation (pre-referral) August 2010

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): appendix C - provisional matrix (pre-referral) August 2010